A groundbreaking study published in Frontiers in Neuroscience showcases the additive neuroprotective effects of a combination of tauroursodeoxycholic acid (TUDCA), coenzyme Q10 (CoQ10), and creatine in in-vitro models of Parkinson’s disease.
This research demonstrates:
Improved neural network density in dopaminergic neurons.
Significant reduction in pro-inflammatory cytokines, particularly TNF-α and IL-6.
Enhanced mitochondrial function and oxidative stress mitigation.
💡 Why This Matters:
The multi-target approach could serve as a model for tackling neurodegenerative diseases like ALS.
It paves the way for future preclinical and clinical trials to improve patient outcomes.
At Haim Pharma, we are inspired by such advancements. It aligns with our mission to innovate therapies for neurodegenerative diseases by focusing on multi-faceted, targeted solutions.
🔗 Read the full study here
A great study by Alexander Shtilbans, Wolfgang E. Reintsch, Valerio E. C. Piscopo, Andrea I. Krahn, Thomas M. Durcan.
